Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Scientific Reports|July 16, 2022
High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrenceSandrine Nugteren, Sjoerd H den Uil, Pien M Delis-van Diemen, et al.
Journal of Surgical Oncology|November 20, 2013
Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrenceEric J Th Belt, Hein B A C Stockmann, Pien M Delis-van Diemen, et al.
Oncotarget|July 24, 2018
MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancerEvert van den Broek, Sjoerd H den Uil, Veerle M H Coupé, et al.
Oncotarget|October 13, 2016
Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patientsEvert van den Broek, Oscar Krijgsman, Daoud Sie, et al.
European Journal of Cancer (Oxford, England : 1990)|December 20, 2020
Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancerSjoerd H den Uil, Meike de Wit, Robbert J C Slebos, et al.
BMC Gastroenterology|August 18, 2019
Prognostic value of microvessel density in stage II and III colon cancer patients: a retrospective cohort studySjoerd H den Uil, Evert van den Broek, Veerle M H Coupé, et al.
International Journal of Surgery (London, England)|May 29, 2025
Development and validation of a clinical decision tool for predicting long-term pain reduction following laparoscopic cholecystectomy in patients with symptomatic cholecystolithiasis: a prospective cohort studyDaan J Comes, Carmen S S Latenstein, Jarmila D W van der Bilt, et al.
Oncotarget|July 15, 2015
MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patientsKristiaan Lenos, Jeroen A C M Goos, Ilona M Vuist, et al.
British Journal of Cancer|November 18, 2016
Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrenceSjoerd H den Uil, Veerle M H Coupé, Janneke F Linnekamp, et al.
JAMA Surgery|August 21, 2024
Restrictive Strategy vs Usual Care for Cholecystectomy in Patients With Abdominal Pain and Gallstones: 5-Year Follow-Up of the SECURE Randomized Clinical TrialDaan J Comes, Sarah Z Wennmacker, Carmen S S Latenstein, et al.
Pageof 5